Physician profile
Daniel G Pizana
NPI 1164980827
$4,832.91
in general payments reported to CMS, 2019-2025
22 companies · $866 in 2025
The $866 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $908 · 2022: $982 · 2023: $1,118 · 2024: $959 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.61 |
| Education | $226.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $961.02 | 2022-2025 | Enhertu, Datroway |
| Daiichi Sankyo INC. | $559.93 | 2021-2025 | Enhertu |
| Incyte Corporation | $461.62 | 2021-2023 | Jakafi |
| Gilead Sciences, INC. | $397.95 | 2022-2024 | Trodelvy |
| Stemline Therapeutics INC. | $262.85 | 2023-2024 | Orserdu |
| Caris Mpi, INC. | $257.86 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $249.35 | 2023-2025 | Darzalex, Carvykti, Rybrevant |
| Seagen INC. | $230.46 | 2021 | |
| Exelixis INC. | $224.99 | 2022-2023 | Cabometyx |
| Lilly USA, LLC | $190.22 | 2022-2024 | Verzenio |
| E.R. Squibb & Sons, L.L.C. | $177.70 | 2021-2022 | |
| Pfizer INC. | $154.48 | 2022-2023 | |
| Abbvie INC. | $124.99 | 2023 | |
| Adc Therapeutics America, INC. | $122.69 | 2021 | |
| Rigel Pharmaceuticals, INC. | $106.38 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $87.11 | 2021 | |
| Eisai INC. | $71.51 | 2021-2023 | |
| Astellas Pharma US INC | $69.99 | 2024 | |
| Amgen INC. | $52.04 | 2021-2023 | Xgeva |
| Genentech USA, INC. | $28.05 | 2024 | Itovebi |
| Merck Sharp & Dohme LLC | $27.06 | 2025 | Lynparza, Keytruda, Keytruda Qlex |
| Tempus Ai, INC | $14.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pizana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.